Participated · Equity · Jan 2018

TytoCare develops a clinician-grade handheld remote examination platform paired with FDA-cleared AI-powered software-as-a-medical-device algorithms to enable comprehensive remote physical exams. The company serves health systems, payers, and employer health programs and is positioning its platform for cardiopulmonary screening, oncology supportive care, and chronic disease management including CHF and COPD. TytoCare announced leadership appointments of Adam Pellegrini as CEO and Greg Orr as COO concurrent with its $25M+ growth round led by Insight Partners. The company intends to use the new capital to expand its AI algorithm pipeline, deepen integrations with health systems and payers, and accelerate go-to-market efforts. TytoCare is headquartered in New York and Netanya, Israel, and emphasizes FDA-cleared diagnostic fidelity as a competitive differentiator.

Participated · Equity · Jul 2016

Caremerge provides a cloud-based care coordination and communication platform that leverages cross-enterprise workflow automation to deliver the right information to the right provider at the right time. Its platform acts as a connector across the care continuum, bringing together hospitals, MCOs, ACOs, physicians, long-term care providers, families and patients. Product offerings include clinical and compliance solutions, life enrichment and engagement tools, OPEN API integrations for interoperability with leading EHRs, CMS value-based care solutions, and hospital discharge and patient tracking into post-acute care. The company is led by CEO and co-founder Asif Khan. Caremerge plans to use the new funding to expand operations across the post-acute care market. The article notes a $14M financing round but does not disclose other operating metrics. Caremerge provides a HIPAA-compliant mobile and internet-based platform that enables staff at senior care facilities to communicate with doctors and family members about treatment. The company aims to unify communications among family members, designated caregivers, and medical providers to improve coordination of elder care. Caremerge initially launched in 2012 and is based in Chicago. Its product is targeted at senior care facilities and their networks of clinicians and relatives. The company recently raised institutional funding to support its work in the aging-care sector. The funding round included strategic and venture investors with senior-care and health-industry focus. Caremerge offers a suite of apps that run on PCs, tablets and smartphones to help long-term care providers, physicians and families coordinate care of seniors. Its features include saving and organizing communications with family members, capturing and sharing clinical notes and observations, and automating reminder calls and activity notifications. The company says its platform loops in long-term care facilities, physicians, family members and seniors without relying on the elderly population to use computers and smartphones. Caremerge was founded in 2010 by Asif Khan, who previously worked eight years at GE Healthcare IT, and is based in Chicago. With a $2.1 million infusion from angel investors, the company plans to continue expanding and improving the platform. Caremerge has also formed a commercial partnership with InnovateLTC and is participating in a three-year entrepreneurship program run by StartUp Health and GE.

Led · Series A · Apr 2016

mPulse Mobile provides conversational AI and tailored digital health engagement, combining a healthcare conversational platform with streaming health education to nurture, educate, and activate consumers. The company reports more than a decade of experience, 150+ healthcare customers and roughly 500 million conversations annually. After acquiring HealthCrowd, mPulse says its combined reach supports over 100 million patients and health plan members and expands capabilities in Medicaid and hard-to-reach populations. HealthCrowd serves four out of five of the country’s top managed care organizations and manages lives in 34+ states, bringing complementary communications platform expertise. The company plans to use new funding to accelerate go-to-market expansion, enable product innovation, and pursue organic and inorganic growth. Financial terms of the transactions were not disclosed, though PSG became the majority shareholder. mPulse Mobile provides conversational AI solutions for healthcare that combine behavioral science, analytics and industry expertise to drive healthy behaviors. Led by CEO Chris Nicholson, the company enables healthcare organizations to activate their consumers and improve engagement. It serves more than 100 healthcare customers and powers over 300 million conversations annually. mPulse plans to use recent funding to expand its consumer conversational AI capabilities, enhance its client engagement analytics platform and broaden engagement solutions across healthcare verticals. The company recently closed a Series C round of more than $16M. mPulse Mobile provides mobile solutions for the healthcare industry designed to engage and activate consumers through tailored mobile dialogues. The company launched its Activation Intelligence product, which leverages demographic, psychographic and patient-generated data to dynamically profile users and deliver individualized mobile dialogues. Activation Intelligence is already in production in an Integrated Delivery Network diabetes self-management study covering a diverse population of more than 8,000 patients and automating tens of thousands of tailored mobile dialogues; study results will be published later this year. mPulse added 26 new clients and partners across multiple healthcare segments, including Cambia Health Solutions, Magellan Health, CityMD, Premera Blue Cross, Catasys, Docent Health and Healthx. The company intends to use the funds for market growth through strategic acquisitions and further investment in data science and artificial intelligence technology solutions. Led by co-founder and CEO Chris Nicholson, mPulse has raised a total of more than $25M to date following the Series B. mPulse Mobile spun out of secure mobile messaging company mobileStorm about a year ago to focus on the healthcare sector, which was mobileStorm's fastest-growing area. Its core product is a secure messaging platform that can send SMS, power a secure website messaging service, or be integrated into a healthcare organization’s existing app. The company serves payers, pharmacies, providers, and medical device companies and says its customer base exceeds 50 healthcare organizations. mPulse is working with Inland Empire Health Plan to engage Medi‑Cal beneficiaries and is launching pilots with other Medi‑Cal plans. Management describes communicating with hard-to-reach populations and engaging them in their health as a core company strategy. The company’s total funding has reached just over $14 million following its most recent investment. mPulse Mobile provides mobile engagement solutions for health plans, providers, and pharmaceutical companies, focusing on two-way secure messaging and consumer outreach. Its platform targets missed appointments, medication adherence, and gaps in care to improve outcomes and lower costs. The company reports more than 50 U.S. health plan, provider, and pharmaceutical clients. mPulse was granted a U.S. patent for its secure mobile messaging solution. Financially, it has raised over $13M in venture funding to date and closed an oversubscribed Series A. The company plans to hire roughly 20 team members across tech, behavioral science and analytics, account management, and sales and marketing.

Participated · Series C · Mar 2016

Maxwell Health offers a Health-as-a-Service platform that serves as an operating system for employee benefits, engaging employees and providing a centralized place to access health and benefits services. Its web portal and mobile app leverage data from multiple sources to enable more informed health solutions. The company’s technology is licensed by benefits brokers, TPAs, insurance carriers, PEOs, and other vendors for direct use with their employer clients. Led by Veer Gidwaney, Maxwell operates a marketplace of insurance, lifestyle, and financial products alongside its core platform. Following the recent fundraise the company plans to continue investing in its benefits and HR platform, its marketplace, and partner-facing solutions to serve small and mid-sized businesses across the country. Maxwell has raised $56.4M to date, including the newly closed Series C. Maxwell Health provides a Health-as-a-Service platform comprising a marketplace, a comprehensive benefits-administration system, and a mobile/web portal where employees access benefits, navigate healthcare, and manage health and wealth. The platform aggregates data from integrated services to deliver more informed health solutions and is licensed by benefits brokers, TPAs, carriers, and other vendors for use with their employer clients. Employers can offer fully- and self-insured medical plans, exchange products, dental, vision, life, disability, and financial benefits such as 401(k) and HRA/HSA/FSA through Maxwell’s system. Maxwell integrates third-party services including Doctor on Demand (telemedicine), Care.com (child care), Health Advocate (concierge services), HelloFresh (meal delivery), ID Watchdog (identity-theft protection), and BioIQ (biometric screening). Led by CEO and co-founder Veer Gidwaney, the company plans to use new funding to grow its team and continue expanding product functionality. The company operates from Boston, MA and New York, NY. Maxwell Health provides an enterprise software platform that helps brokers and employers (targeting companies with fewer than 1,000 employees) create and manage health insurance, payroll and a range of employee benefits, including 401(k)s. Launched in February, the company partners with insurance brokers—brokers pay monthly fees and the platform is free for employers—rather than trying to replace brokers. Its product set includes HR functionality from onboarding to retirement planning, private benefit exchanges that sync with existing plans, an employee incentivization system tied to fitness device data, and a concierge service that helps file claims, compare prescriptions and schedule appointments. The company reports a customer base "well into the triple digits," membership doubled over the prior six weeks, and revenue doubled quarter-over-quarter over the last six months. With new capital, Maxwell plans to invest heavily in customer service and to ramp up its sales and engineering teams. Maxwell Health operates a no-cost benefits-management platform for businesses that centralizes enrollment and administration for medical, dental, vision, life, disability, COBRA, HRA/HSA, FSA and 401(k). The platform gives employees a broader selection of insurance plans, advice on which to choose, and a portal to manage existing plans; employers get a dashboard to track hiring, employee engagement and company spending. Maxwell earns commissions on insurance plans chosen through the service. The company has dozens of businesses on board and is licensed to serve employers in 24 states. It launched in February and offers a concierge service that handles bills, insurance disputes and medical appointments, plus a wellness incentives program using fitness devices and points redeemable for rewards. Planned product additions include nurse on-call services and tracking/management for nutrition, sleep and stress. CEO and co-founder Veer Gidwaney said the new funding will be used to add features, increase outreach and build distribution.

Participated · Series C · Dec 2015

GNS Healthcare is a precision medicine company based in Cambridge, Mass., led by Chairman, CEO and Co‑Founder Colin Hill. Its core product is the REFS causal learning and simulation platform, which analyzes data sets beyond correlation to infer causal mechanisms between variables. The platform is designed to answer questions such as how a patient will respond to a treatment and what would happen if one intervention is chosen over another. GNS targets health plans, biopharma companies, and health systems to address healthcare’s matching problem by transforming massive, diverse data streams to match therapeutics, procedures, and care-management interventions to individuals. Following its Series D, the company intends to use the funds to expand its business reach. GNS Healthcare develops REFS™ (Reverse Engineering & Forward Simulation), a patented causal machine learning and simulation platform that infers causal mechanisms from multimodal datasets and runs “what if?” simulations to predict individual treatment responses. The company delivers cloud-based solutions for health plans, biopharmaceutical companies, providers, foundations, academic medical centers, and self-insured employers. Customers use GNS to address problems including metabolic syndrome, medication adherence, end-of-life care, preterm birth, personalized specialty-care pathways, oncology, diabetes, new drug target discovery, and patient stratification in clinical trials. Led by Chairman and CEO and co-founder Colin Hill, GNS emphasizes using causality rather than correlation to guide interventions and therapeutic selection. The company plans to further develop REFS across drug discovery & development, value-based drug solutions, care management, and health‑system business optimization. The article reports a $6m equity investment to support those development efforts. GNS Healthcare applies patented causal machine learning and its REFS™ (Reverse Engineering and Forward Simulation) simulation engine along with the MeasureBase™ data integration architecture to analyze rich patient data streams. The company integrates electronic medical records, claims, genomics, mobile device data, and consumer behavior to identify individuals at risk and match them to the most effective interventions. Its cloud-based solutions are used by health plans, biopharmaceutical companies, healthcare providers, foundations, academic medical centers, and employers to address issues such as medication adherence, preterm birth, metabolic syndrome, and patient stratification in clinical trials. GNS focuses on reducing adverse events, slowing disease progression, and improving therapeutic effectiveness while lowering downstream medical costs. The company recently announced an investment from Horizon Healthcare Services to expand a strategic partnership and enable further development and validation of novel cloud-based precision-medicine solutions in population health. GNS Healthcare develops cloud-based, data-driven solutions that apply patented causal machine learning and its REFS™ (Reverse Engineering and Forward Simulation) engine to predict which treatments will work for which patients. The company integrates diverse patient data — including electronic medical records, mobile health devices, claims, genomics, and consumer behavior — to help health plans, biopharma, providers, foundations, academic researchers, and employers. Its platform (MAX™ data architecture and REFS™ engine) is used for patient stratification, comparative effectiveness, drug target discovery, addressing medication non-adherence, preterm birth, end-of-life care, metabolic syndrome, diabetes, and specialty care. GNS licenses these solutions to customers and aims to accelerate development of new cloud-based big data offerings at the intersection of precision medicine and population health. The company emphasizes using causal inference and simulation to reveal cause-and-effect relationships and to support point-of-care and research decision-making. GNS has been active in the precision medicine movement since 2000 and positions its technology to improve outcomes while reducing costs. GNS Healthcare develops patented big data analytics methods to build predictive models and products for pharmaceutical companies, health plans and providers. Its tools address population health management questions such as predicting individual and population risk and costs, comparing treatment effectiveness, targeting member engagement to improve medication adherence, and discovering biomarkers that predict patient response to medications. Led by CEO Colin Hill, the company sells analytics products and services across the healthcare sector. GNS completed a $10M Series B financing and intends to use the funds to expand its data analytics business across the healthcare industry. The company is based in Cambridge, MA.